drugset / Trial / NCT02578771

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

NCT02578771

Phase 3 Completed 123 enrolled Zurex Pharma, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive control will be compared; ZuraPrep non-active and negative control will be compared. Each subject will receive two of the planned treatments, one on the left side of body and one of the right. Study duration for subjects - 3 to 4 weeks.

Timeline

Start
2015-10
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorhexidine Small molecule Topical
Subject ZuraPrep Unknown Topical

Indications

No indication recorded.